Showing 5221-5230 of 5960 results for "".
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- Cynosure Receives Health Canada Authorization to Market SculpSure®https://practicaldermatology.com/news/cynosure-receives-health-canada-authorization-to-market-sculpsure/2458503/Cynosure, Inc. received Health Canada Authorization to Market SculpSure® for non-invasive lipolysis of the abdomen and flanks. SculpSure is a fat-reduction laser intended for individuals with a body mass index (BMI) of 30 or less. The
- Topix Pharmaceuticals Partners with New Mountain Capitalhttps://practicaldermatology.com/news/new-mountain-capital-partners-with-topix-pharmaceuticals/2458505/Topix Pharmaceuticals, Inc. has partnered with New Mountain Capital, LLC, a growth-oriented investment firm that currently manages over $15 billion in assets. New Mountain, a New York-based private equity firm, identified Topix through a proactive focus in the life sciences and aestheti
- Sciton Launches New Program to Encourage Practice Growthhttps://practicaldermatology.com/news/sciton-launches-new-program-to-encourage-practice-growth/2458510/Sciton Inc. is unveiling their new practice support program. With Success Builder, Sciton offers four specialized pillars: clinical training, marketing tools, business development, and Sciton-sanctioned tools and courses. Many of the vendors also o
- Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Submental Fullnesshttps://practicaldermatology.com/news/allergan-receives-positive-opinion-through-european-decentralised-procedure-for-belkyra-deoxycholic-acid-for-submental-fullness/2458511/The Swedish Medical Products Agency (MPA) gave its thumbs up to Allergan’s BELKYRA® (deoxycholic acid). BELKYRA® is being
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme